Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano,

Slides:

Advertisements

Similar presentations

A Loh, PY Boey & RS Loh Singapore National Eye Centre World Cornea Congress VI Boston, Massachusetts, April 7-9, 2010 The authors have no financial interests.

Advertisements

Sérgio Kwitko, Tiago Lansini, Andressa P Stolz, Diane R Marinho Authors have no financial interest in the subject matter of this poster.

Ocular Manifestations Stella K. Kim, M.D. MD Anderson Cancer Center Houston, TX Michael R. Robinson, M.D. National Eye Institute National Institutes of.

ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.

Physician Compliance With the HEDS Recommendation of Antiviral Prophylaxis in Patients Diagnosed With Herpetic Stromal Keratitis at KEI Sameen Zaidi M.D.

Vatinee Y. Bunya, MD, Mina Massaro-Giordano, MD, Frederick B. Vivino, MD*, Stephen E. Orlin, MD, Michael E. Sulewski, MD, and Maureen G. Maguire, PhD The.

‘‘DRY EYE’’. Dry Eye Dry eye is a disease of the ocular surface attributable to different disturbances of the natural function and protective mechanisms.

The authors have no financial interest in the subject matter of this e-poster. Thomas John, MD 1 Alissa Pullos 1- Loyola University at Chicago.

Incidence of Blepharitis in Patients Undergoing Phacoemulsification Jodi Luchs, MD Carlos Buznego, MD William Trattler, MD The authors of this poster have.

Relationship Between Donor Graft Cell Count and Visual Outcome in DSAEK Patients Authors Silvin Bakalian MD PhD, Johanna Choremis MD FRCSC, Michele Mabon.

RED EYE, a Differential Diagnosis M. F. Al Fayez, MD, FRCS.

Multi-Drug Resistant Pseudomonas Keratitis Clinical Characteristics and Associated Features Jayesh Vazirani Merle Fernandes L V Prasad Eye Institute Visakhapatnam,

OPHTHALMOLOGY UPDATE Ajay Bhatnagar Consultant Ophthalmologist

Long-Term Outcome of Corneal Transplant Surgery in Pediatric Patients with Keratoconus Anna Djougarian, MD Hofstra / North Shore-LIJ Medical Center Gerald.

Bilateral Corneal Trophic Ulcers and Subsequent Infectious Keratitis in a Patient with Graft-versus-host Disease Yonca Aydın Akova, MD Bayındır Hospital,

DR WEI BOON KHOR FRCSED, FAMS CONSULTANT CORNEA AND EXTERNAL EYE DISEASE SERVICE SINGAPORE NATIONAL EYE CENTRE I HAVE NO FINANCIAL INTERESTS IN THE SUBJECT.

Siamak Zarei-Ghanavati M.D., FICO

1. Vision Changes  You may notice vision changes with aging.  Many changes are common and can often be corrected.  As you get older, you are at higher.

Young Joo Shin 1, Joo Hyun Kim 1, Jung Ha Kim 2, Woo Ho Nam 1, Kayoung Yi 1, Joon Young Hyon 3, 1 Department of Ophthalmology, Hallym University College.

W. B. Trattler; C. D. Reilly; D. F. Goldberg; P. A. Majmudar; J. A. Vukich; M. Packer; E. D. Donnenfeld.

Presented at the 15 th Congress of the European Society for Organ Transplantation, 4-7 September 2011, Glasgow, Scotland References Conclusions Objectives.

Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano,

Elvin H. Yildiz, Elisabeth J. Cohen, Ajoy S. Virdi, Kristin M. Hammersmith, Peter R Laibson, and Christopher J. Rapuano Cornea Service, Wills Eye Institute,

Management of Methicillin- Resistant Staphylococcus Aureus Keratitis in Post-surgical Patients: Two Case Reports Sujata P. Prabhu, MD and Timothy Y. Chou,

Association between Depression And Dry eye Sang Beom Han, MD, 1 Joon Young Hyon, MD, 1 Young Joo Shin, MD, 1 Won Ryang Wee, MD, 2 Jin Hak Lee, MD, 1 1.

Blepharitis and Dry eyes in Aromatase Inhibitor Users

Corneal Disease and Mitochondrial Cytopathy: Report of Two Unrelated Individuals Jocelyn Kim, BA, Anagha Medsinge, MD, Bharesh Chauhan, PhD, Cara Wiest,

Somasheila I. Murthy, Prashant Garg, Pravin K. Vaddavalli

Dry Eyes and Blepharitis Mitch Menage Consultant Eye Surgeon Leeds Teaching Hospitals Trust Mitch Menage Consultant Eye Surgeon Leeds Teaching Hospitals.

Autologous serum eye drops in severe post-LASIK dry eye.

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

Topical Tacrolimus 0,03% for Treatment of Refractory Allergic Conjunctivitis Diane Marinho, Andréia Ferreira Laranjeira, Sérgio Kwitko, Samuel Rymer Hospital.

Characterization of Higher Order Ocular Aberrations (HOA) In ‘Normal’ Versus Myopic Eyes To Study The Effect Of Myopia On Higher Order Aberrations Amit.

Ten-year Clinicopathological Review Of Ocular Surface Squamous Neoplasia In An Ophthalmological Center In Mexico City Lucero Pedro-Aguilar, M. D. Alvarez-Melloni.

Comparison of Bromfenac vs. Ketorolac During the Induction Phase of Treatment with Topical Cyclosporine for Dry Eye Patients Barry A. Schechter, MD Florida.

Persistence and Prevalence of MRSA on Ocular Surface following Primary MSSA/MRSA Infections Darlene Miller, DHSc, MPH, CIC David Almeida, MD, PhD Eduardo.

Evaluation of Systane® versus Placebo in Corneal Epithelial Healing Following Photorefractive Keratectomy (PRK) Lt Col Charles D. Reilly Major Vasudha.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

FLUORESCEIN CLEARANCE TEST AS AN ADDITIONAL DIAGNOSTIC TOOL FOR DYSFUNCTIONAL TEAR SYNDROME Rodrigo de Nápole Azevêdo, MD Jamília Barros da Silva, MD Aline.

Wait time and Vision and Health Problems in Adults Expecting Corneal Transplantation at a Hospital in Montreal, Canada M Alizadeh-Ebadi MD, H Boisjoly.

Prospective Correlation of Symptoms and Clinical Grading in Vernal Keratoconjunctivitis Patients Srikant K Sahu, Shraddha Pawan Sureka, Sujata Das, Apurva.

David R. Hardten 1, Mark Milner 2, Jai G. Parekh 3, Neda Shamie 4, Darrell E. White 5 and Michael Schiewe 6 Financial Disclosures: Dr’s Hardten, Milner,

Severity of Herpes Zoster Ophthalmicus: Onset at Younger Than 60 Years Versus 60 Years or Older Neelofar Ghaznawi MD, Ajoy Virdi MD, Amir Dayan, Christopher.

Prevalence of Dry Eye Disease among Elderly Korean Population Sang Beom Han, MD, 1 Joon Young Hyon, MD, 1 Won Ryang Wee, MD, 2,3 Jin Hak Lee, MD, 1, 3.

Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.

Mark Dacey MD, Brian Sullivan MD, and Steven Verity MD University of Texas Southwestern Medical Center and VA Medical Center, Dallas, TX None of the authors.

Correlation of Conjunctival and Corneal Staining With Elevated Matrix Metalloproteinase-9 on the Ocular Surface of Dry-Eye Patients Authors: Allister Gibbons,

Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.

Topical Cyclosporine 0.05% as a Long-Term Monotherapy for Atopic Keratoconjunctivitis Jonathan H. Tzu, M.D ¹, * ; C. Asli Utine, M.D ¹,², * Michael Stern,

Corneal Disease.

Ocular functional optical zone following hyperopic LASIK/PRK: Analysis based on polychromatic retinal image quality Mitchell P. Weikert, MD Li Wang, MD,

Ocular Response Analyzer Waveform Analysis in the Ectatic Corneas: Correlation of the New Corneal Biomechanics Parameters and Severity of Keratoconus Kristin.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Comparison of Efficacy of 0.05% Cyclosporine Ophthalmic Emulsion

Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,

ID: 287 Fusarium keratitis in a tertiary eye care centre in India Sujata Das, MS, FRCS Savitri Sharma, MD Samir Mahapatra, MS Srikant K Sahu, MS L V Prasad.

Elmira Baghdasaryan1,2, M.D. Sophie X. Deng1, M.D., Ph.D.

Yonca Aydin Akova MD, Leyla Erkanli Asena MD

UC Davis Long-Term Outcomes of the Boston Type I Keratoprosthesis Jennifer Li, M.D., Mark Greiner, M.D. Ana Carolina Vieira, M.D. Mark Mannis, M.D. University.

Role of a Sutureless Amniotic Membrane Patch in Restoring the Corneal Surface Anterior Segment OCT Assessment Roxana Ursea, MD Matthew T. Feng, MD The.

Department of Cornea, Cataract & Refractive Surgery and *Ocular Microbiology Dr Rajendra Prasad Centre For Ophthalmic Sciences, AIIMS Dr. Manoj Sharma,

Corneal Biomechanical Changes Following Surface Keratorefractive Surgery Teeravee Hongyok, MD, Christopher J. Rapuano, MD, Ajoy Virdi, MBBS, Elisabeth.

Management of corneal perforations and deep ulcers with patch grafts Dariusz Dobrowolski¹, Edward Wylęgała¹ ׳ ², Dorota Tarnawska¹, Dominika Janiszewska¹.

The Course of Dry Eye After Phacoemulsification Surgery Servet Cetinkaya 1, Emine Mestan 2, Nursen Oncel Acir 3, Yasemin Fatma Cetinkaya 4, Zeynep Dadaci.

EVALUATION OF OCULAR SURFACE DISEASE IN PATIENTS AFTER TRABECULECTOMY: COMPARATIVE STUDY WITH AND WITHOUT INTRACAMERAL BEVACIZUMAB Sónia Parreira; Sandra.

Jodi Luchs, MD Carlos Buznego, MD William Trattler, MD

From: Cultured Autologous Oral Mucosal Epithelial Cell Sheet (CAOMECS) Transplantation for the Treatment of Corneal Limbal Epithelial Stem Cell Deficiency.

Eric Dai MD, Pawan Prasher MD, James McCulley MD, R. Wayne Bowman MD.

Yumiko Ban,1,2,3) Seika Den,2) Jun Shimazaki,2,3)

I-Chan Lin MD, Paul P. Lee MD, JD

Presentation transcript:

Blepharitis and Dry eyes in Aromatase Inhibitor Users Kiran Turaka, M.D. Kristin M. Hammersmith, M.D. Jennifer M. Nottage, M.D. Christopher J. Rapuano, M.D. Wills Eye Institute, Philadelphia PA The authors have no financial interest in the subject matter of this e-poster in the subject matter of this e-poster

Purpose Anastrazole (Arimidex®) Aromatase inhibitor (AI), suppress estrogen synthesis from the androgens Aromatase inhibitor (AI), suppress estrogen synthesis from the androgens Used as an adjuvant therapy in breast/ovarian cancer treatment Used as an adjuvant therapy in breast/ovarian cancer treatment Investigation of an association between anastrazole and dry eye syndrome Investigation of an association between anastrazole and dry eye syndrome

Methods Retrospective chart review Retrospective chart review Computerized search of Wills Cornea Service electronic health records between from August 2008 to April Computerized search of Wills Cornea Service electronic health records between from August 2008 to April Results were compared with the age-matched controls from a published study by Schaumberg et al. 1 Results were compared with the age-matched controls from a published study by Schaumberg et al Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003; 136:

Results Total patients on anastrazole=16 Caucasian women Total patients on anastrazole=16 Caucasian women Breast cancer= 15 (94%) Breast cancer= 15 (94%) Ovarian cancer = 1 (6%) Ovarian cancer = 1 (6%) Mean ± SD age was 67 ± 13 years (range 50-95) Mean ± SD age was 67 ± 13 years (range 50-95) Best corrected VA was better than 20/40 in 24 (75%) Best corrected VA was better than 20/40 in 24 (75%)

Systemic Features Characteristic feature Total patients, N= 16 (%) Treatment of primary cancer Surgery Surgery 9 (56) Chemotherapy Chemotherapy 4 (25) Radiotherapy Radiotherapy 2 (13) Past medical history Diabetes Mellitus Diabetes Mellitus 5 (31) Hypertension Hypertension 5 (31) Hypercholesterolemia Hypercholesterolemia 1 (6) Hyperthyroidism Hyperthyroidism 2 (13)

Associated Ocular conditions Characteristic feature Total patients, N=16 (%) Blepharitis 4 (25) Fuch ’ s dystrophy 4 (25) Dry eye 6 (38) Glaucoma 2 (13) Keratoconus PBK, Ptosis, allergic conjunctivitis, fungal ulcer, chronic conjunctivits 1 each (6)

Ocular Symptoms Characteristic feature Total patients, N= 16 (%) Blurring vision 7 (44) Redness 2 (13) Irritation/foreign body sensation 8 (50) Tearing 4 (25) Photosensitivity 1 (6) Prior Punctal plug use 2 (13) Asymptomatic Among the control population (65-69 years), dryness and irritation were found in 5.7% and 0.6% respectively. 1 Among the control population (65-69 years), dryness and irritation were found in 5.7% and 0.6% respectively. 1

Clinical Features Characteristic feature Total eyes, N=32 (%) Mean ± SD Schirmer test (median, range) mm 11 ± 5.8 (13, ) Decreased tear film 8 (25) Poor tear film 8 (25) Belpharitis 25 (78) Ectropion/entropion 1 (3) Follicular conjunctivitis/injection 10 (31) Superficial Punctate Keratitis 11 (34) Corneal edema 2 (6) Iritis

Slit lamp photograph showing blepharitis and crusts (A), and superficial punctate keratitis (B) on fluorescein staining

Treatment Tear supplement: 15 patients Tear supplement: 15 patients Lubricating ointment/gel: 3 patients Lubricating ointment/gel: 3 patients Antibiotic ointment: 3 patients Antibiotic ointment: 3 patients Punctal plugs: 2 patients Punctal plugs: 2 patients Cyclosporine (topical 0.05%): 2 patients Cyclosporine (topical 0.05%): 2 patients Warm compresses: 2 patients Warm compresses: 2 patients

Summary at the Last follow-up No. of patients at the follow up = 11 (69%) No. of patients at the follow up = 11 (69%) No of patients lost to follow up= 5 (31%) No of patients lost to follow up= 5 (31%) No of patients on Anastrazole = 10 (91%) No of patients on Anastrazole = 10 (91%) Mean ± SD follow-up = 14 ± 7.7 months (range 2-25) Mean ± SD follow-up = 14 ± 7.7 months (range 2-25) After treatment of dry eyes: After treatment of dry eyes: Persistent dry eye symptoms = 3 (27%) Persistent dry eye symptoms = 3 (27%) Mild discomfort = 1 (9%) Mild discomfort = 1 (9%) Best corrected VA was better than 20/40 in 18 (82%) Best corrected VA was better than 20/40 in 18 (82%) Tumor status: Tumor status: Remission of breast cancer = 9 (81%) Remission of breast cancer = 9 (81%) Remission of ovarian cancer = 1 (9%) Remission of ovarian cancer = 1 (9%) Systemic metastasis = 1 (9%) Systemic metastasis = 1 (9%)

Conclusions The prevalence of ocular surface disease appears to be higher in the patients taking anastrazole than in age-matched control population 1 The prevalence of ocular surface disease appears to be higher in the patients taking anastrazole than in age-matched control population 1 Anastrazole is likely a contributing factor to dry eye symptoms Anastrazole is likely a contributing factor to dry eye symptoms A larger scale investigation is necessary to evaluate this correlation further A larger scale investigation is necessary to evaluate this correlation further